ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis

Microvascular Research

Volumn 84, Issue 2, 2012, Pages 109-115

  Lee, Manfai ^a   Rodansky, Eva S ^a   Smith, Justin K ^a   Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN 1; VASCULOTROPIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN DOMAIN; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAM PROTEINS; ANTIBODIES; BINDING SITES; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864005561     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.05.004     Document Type: Article

References (33)

1. Banno F., et al. The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice. Int. J. Hematol. 2010, 91:30-35.
2. Basile D.P., et al. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am. J. Physiol. Renal Physiol. 2008, 294:F928-F936.
3. Cao W.J., et al. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J. Thromb. Haemost. 2008, 6:1233-1235.
4. Cauwe B., et al. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2007, 42:113-185.
5. Dong J.F., et al. ADAMTS13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial cell surface under flowing conditions. Blood 2002, 100:4033-4039.
6. Feys H.B., et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J. Thromb. Haemost. 2006, 4:955-962.
7. Fujikawa K., et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
8. Furlan M., et al. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87:4223-4234.
9. Gerritsen H.E., et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001, 98:1654-1661.
10. Good D.J., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6624-6628.
11. Iba K., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and trigger signaling events that lead to beta 1 integrin-dependent cell spreading. J. Cell Biol. 2000, 149:1143-1156.
12. Kling S.J., et al. Regulation of ADAMTS13 expression in proliferating human umbilical vein endothelial cells. Pathophysiol. Haemost. Thromb. 2007, 36:233-240.
13. Kremer Hovinga J.A., et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J. Thromb. Haemost. 2007, 5:2284-2290.
14. Levy G.G., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
15. Luque A., et al. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 2003, 278:23656-23665.
16. Martin K., et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit. Care Med. 2007, 35:2375-2382.
17. Moake J.L., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1982, 307:1432-1435.
18. Ohtsu H., et al. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell. Physiol. 2006, 291:C1-C10.
19. Reiter R.A., et al. Changes in ADAMTS13 (von Willebrand factor-cleaving protease) activity after induced release of on Willebrand factor during acute systemic inflammation. Thromb. Haemost. 2005, 93:554-558.
20. Rodriguez-Manzaneque J.C., et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12485-12490.
21. Sanderson M.P., et al. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 2006, 24:121-136.
22. Sharghi-Namini S., et al. The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2008, 371:215-219.
23. Soejima K., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J. Biochem. 2001, 130:475-480.
24. Starke R.D., et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011, 117:1071-1080.
25. Stepanian A., et al. Von Willebrand Factor and ADAMTS13, a candidate couple for preeclampsia pathophysiology. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1703-1709.
26. Taraboletti G., et al. The heparin binding 25kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 2000, 14:1674-1676.
27. Tolsma S.S., et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 1993, 122:497-511.
28. Tsai H.-M. Physiologic cleavage of von Villebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996, 87:4235-4244.
29. Turner N., et al. Human endothelial cells synthesize and release ADAMTS13. J. Thromb. Haemost. 2006, 4:1396-1404.
30. Zhang X.P., et al. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 1998, 273:7345-7350.
31. Zheng X., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 2001, 276:41059-41063.
32. Zhou W., et al. ADAMTS13 is expressed in hepatic stellate cells. Lab. Invest. 2005, 85:780-788.
33. Zigrino P., et al. Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J. Biol. Chem. 2007, 282:30785-30793.